KPRX
KPRX clinical trials: KIORA PHARMACEUTICALS INC
Every trial on ClinicalTrials.gov where KIORA PHARMACEUTICALS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 18
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KPRX on the catalyst calendar · KPRX registry changes
- Primary completion Nov 2026Sponsor estimatePhase 2NCT06825702Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular EdemaKiora Pharmaceuticals, Inc. · Macular EdemaRecruitingKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 2NCT06628947A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaKiora Pharmaceuticals, Inc. · Retinitis PigmentosaRecruitingKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 10, 2023ActualPhase 1/Phase 2NCT05282953A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With...Kiora Pharmaceuticals, Inc. · Retinitis PigmentosaCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2022ActualPhase 2NCT05436288A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial DefectsKiora Pharmaceuticals, Inc. · Persistent Corneal Epithelial DefectCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 9, 2024ActualPhase 2NCT05629364A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle...Kiora Pharmaceuticals, Inc. · Dry Eye DiseaseTerminatedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2018ActualNo phase registeredNCT03163641Safety and Effectiveness of OBG vs.a Bandage Contact Lens for Large Corneal Epithelial Defects in Patients Post-PRK.Eyegate Pharmaceuticals, Inc. · Corneal Epithelial WoundCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2019ActualNo phase registeredNCT03938883Ocular Bandage Gel (OBG) Pivotal Trial in Patients Undergoing Photorefractive Keratectomy ("PRK")Eyegate Pharmaceuticals, Inc. · OphthalmologyCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2012ActualPhase 2NCT01602068Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOLEyegate Pharmaceuticals, Inc. · CataractCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 20, 2018ActualPhase 3NCT02517619Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior UveitisEyegate Pharmaceuticals, Inc. · Anterior UveitisCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 7, 2017ActualPhase 2NCT03180255Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract SurgeryEyegate Pharmaceuticals, Inc. · CataractCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2016ActualPhase 1NCT02644694PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing VitrectomyEyegate Pharmaceuticals, Inc. · VitrectomyCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2016ActualPhase 1/Phase 2NCT02571556OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE...Eyegate Pharmaceuticals, Inc. · Patients Having Undergone Unilateral Cataract Extraction and Implantation of a MonofocalCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2016ActualPhase 1/Phase 2NCT02485249Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone...Eyegate Pharmaceuticals, Inc. · Macular EdemaTerminatedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2013ActualPhase 3NCT01505088Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment UveitisEyegate Pharmaceuticals, Inc. · Anterior UveitisCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2011ActualPhase 3NCT01129856Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry EyeEyegate Pharmaceuticals, Inc. · Dry EyeCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2009ActualPhase 2NCT00765804Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry EyeEyegate Pharmaceuticals, Inc. · Dry Eye SyndromeCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2009ActualPhase 2NCT00694135Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior UveitisEyegate Pharmaceuticals, Inc. · Uveitis, AnteriorCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2008ActualPhase 1NCT00698425Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device SystemEyegate Pharmaceuticals, Inc. · HealthyCompletedKPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner